Literature DB >> 35864190

Loss of FOCAD, operating via the SKI messenger RNA surveillance pathway, causes a pediatric syndrome with liver cirrhosis.

Ricardo Moreno Traspas1,2, Tze Shin Teoh3,4, Pui-Mun Wong3, Michael Maier3, Crystal Y Chia3, Kenneth Lay3, Nur Ain Ali3, Austin Larson5, Fuad Al Mutairi6,7, Nouriya Abbas Al-Sannaa8, Eissa Ali Faqeih9, Majid Alfadhel6,10, Huma Arshad Cheema11, Juliette Dupont12, Stéphane Bézieau13, Bertrand Isidor13, Dorrain Yanwen Low14, Yulan Wang14, Grace Tan4, Poh San Lai4, Hugues Piloquet15, Madeleine Joubert16, Hulya Kayserili17, Kimberly A Kripps18, Shareef A Nahas19, Eric P Wartchow20, Mikako Warren21, Gandham SriLakshmi Bhavani22, Majed Dasouki23, Renata Sandoval24, Elisa Carvalho25, Luiza Ramos26, Gilda Porta27, Bin Wu28,29, Harsha Prasada Lashkari30,31, Badr AlSaleem32, Raeda M BaAbbad32, Anabela Natália Abreu Ferrão33, Vasiliki Karageorgou34, Natalia Ordonez-Herrera34, Suliman Khan34, Peter Bauer34, Benjamin Cogne13, Aida M Bertoli-Avella34, Marie Vincent13, Katta Mohan Girisha22, Bruno Reversade35,36,37,38,39.   

Abstract

Cirrhosis is usually a late-onset and life-threatening disease characterized by fibrotic scarring and inflammation that disrupts liver architecture and function. While it is typically the result of alcoholism or hepatitis viral infection in adults, its etiology in infants is much less understood. In this study, we report 14 children from ten unrelated families presenting with a syndromic form of pediatric liver cirrhosis. By genome/exome sequencing, we found recessive variants in FOCAD segregating with the disease. Zebrafish lacking focad phenocopied the human disease, revealing a signature of altered messenger RNA (mRNA) degradation processes in the liver. Using patient's primary cells and CRISPR-Cas9-mediated inactivation in human hepatic cell lines, we found that FOCAD deficiency compromises the SKI mRNA surveillance pathway by reducing the levels of the RNA helicase SKIC2 and its cofactor SKIC3. FOCAD knockout hepatocytes exhibited lowered albumin expression and signs of persistent injury accompanied by CCL2 overproduction. Our results reveal the importance of FOCAD in maintaining liver homeostasis and disclose a possible therapeutic intervention point via inhibition of the CCL2/CCR2 signaling axis.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35864190     DOI: 10.1038/s41588-022-01120-0

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   41.307


  76 in total

Review 1.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 2.  Hepatic fibrosis -- overview.

Authors:  Scott L Friedman
Journal:  Toxicology       Date:  2008-07-10       Impact factor: 4.221

Review 3.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

Review 4.  Recent advancement of molecular mechanisms of liver fibrosis.

Authors:  Ekihiro Seki; David A Brenner
Journal:  J Hepatobiliary Pancreat Sci       Date:  2015-04-13       Impact factor: 7.027

Review 5.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Evidence-based clinical practice guidelines for liver cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  Hepatol Res       Date:  2021-07-06       Impact factor: 4.288

Review 7.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

8.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

Authors:  Bi-Sen Ding; Zhongwei Cao; Raphael Lis; Daniel J Nolan; Peipei Guo; Michael Simons; Mark E Penfold; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

9.  Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

Authors:  Christine C Hsu; Juliane S Troeger; Ingmar Mederacke; Peter Huebener; Xueru Mu; Dianne H Dapito; Jean-Philippe Pradere; Robert F Schwabe
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.

Authors:  Ali A Mokdad; Alan D Lopez; Saied Shahraz; Rafael Lozano; Ali H Mokdad; Jeff Stanaway; Christopher J L Murray; Mohsen Naghavi
Journal:  BMC Med       Date:  2014-09-18       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.